Jasper Therapeutics Q1 2025 net loss $21.2M; cash $48.8M; briquilimab programs on track

Jasper Therapeutics, Inc.

2025-Q1 EPS reported -$1.41

Net loss of $21.2M ($1.41 per share) for Q1 2025; R&D expenses $16.2M, G&A $5.6M.
Cash and equivalents totaled $48.8M as of March 31, 2025.
BEACON CSU study data (including OLE) expected first half of Q3 2025; Phase 2b planned for H2 2025.
SPOTLIGHT CIndU study full cohort enrolled; additional data at EAACI June 2025.
ETESIAN asthma allergen challenge study enrolling; initial data expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.